Omadacycline versus Moxifloxacin for the Treatment of Community-Acquired Pneumonia: A Real-World Retrospective Comparative Study of Efficacy and Safety
Abstract
To compare the real-world clinical effectiveness and safety of omadacycline versus moxifloxacin in treating adult patients with CAP.This single-center retrospective cohort study was conducted at the First Affiliated Hospital of Guangxi University of Science and Technology. A total of 348 adult inpatients diagnosed with CAP between June 2022 and December 2024 were enrolled and categorized into the Omadacycline group (n=170) and the Moxifloxacin group (n=178). The primary efficacy endpoint was early clinical response (ECR) assessed 72-120 hours after treatment initiation. Secondary endpoints included overall clinical response rate, bacterial eradication rate, changes in inflammatory biomarkers (WBC, CRP, PCT), and safety outcomes (adverse event incidence).
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 178 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.